Posts Tagged ‘ FOLD ’

Treating Parkinson’s Disease: Investment Opportunities and Challenges

6
August 2, 2009
Treating Parkinson’s Disease: Investment Opportunities and Challenges

Parkinson’s disease is one of the most common of the neurogenerative diseases affecting 1 in 100 people over the age of 60.  Approximately 1.5 million Americans currently suffer from the disease and it is estimated that 60,000 Americans are newly diagnosed each year.  PD is both a chronic and progressive disease. While the...
Read More »

Genzyme’s Manufacturing Disruption Highlights Investment Opportunities in Lysosomal Storage Disorders

1
July 20, 2009
Genzyme’s Manufacturing Disruption Highlights Investment Opportunities in Lysosomal Storage Disorders

Proteins are essential components of the human body.  They perform specific biological functions within a cell and each type of protein has a unique function. For example, enzymes are proteins that help biochemical reactions to occur within the body.  But before they can carry out these important functions, proteins must assemble into precise three-dimensional...
Read More »

Five key principles for life science companies to not only survive – but thrive – in the current environment

0
June 3, 2009
Five key principles for life science companies to not only survive – but thrive – in the current environment

On May 7, 2009, MD Becker Partners LLC hosted its inaugural life sciences roundtable titled “Successful Strategies for Raising Visibility and Capital.” The meeting brought together experts from leading investment banks, life sciences companies, venture investment groups, and the media to discuss the issues surrounding effective two-way communication between a company, the financial community,...
Read More »

Chink in the Biotechnology Armor

2
February 28, 2009
Chink in the Biotechnology Armor

Last week, the NASDAQ Biotech Index (NBI) declined more than 10 percent compared to an approximate 4.5 percent decline for the S&P 500. Since the NBI has been outperforming the broader market since mid-2008, this week’s relative underperformance came as quite a shock to many investors. Trying to explain the decline, most industry pundits...
Read More »